Predictive value of near-term prediction models for severe immune-related adverse events in malignant tumor PD-1 inhibitor therapy
Y Du, Y Zhang, W Zhao, Y Zhang, F Su… - Human Vaccines & …, 2024 - Taylor & Francis
Immune-related adverse events (irAEs) impact outcomes, with most research focusing on
early prediction (baseline data), rather than near-term prediction (one cycle before the …
early prediction (baseline data), rather than near-term prediction (one cycle before the …
[HTML][HTML] Perioperative immunotherapy for stage II-III non-small cell lung cancer: a meta-analysis base on randomized controlled trials
A Yu, F Fu, X Li, M Wu, M Yu, W Zhang - Frontiers in Oncology, 2024 - frontiersin.org
Background In recent years, we have observed the pivotal role of immunotherapy in
improving survival for patients with non-small cell lung cancer (NSCLC). However, the …
improving survival for patients with non-small cell lung cancer (NSCLC). However, the …
Systemic Inflammation Indexes and Risk of Immune-related Adverse Events in Patients With Metastatic Urothelial Carcinoma Treated With Immunotherapy
M Dionese, D Bimbatti, F Pierantoni, E Lai… - Anticancer …, 2024 - ar.iiarjournals.org
Background/Aim: Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of
metastatic urothelial carcinoma (mUC). However, they could be associated with immune …
metastatic urothelial carcinoma (mUC). However, they could be associated with immune …
Efficacy and safety of anti-programmed death-1 antibody-based combination therapy in advanced or metastatic gastric or gastroesophageal junction cancer in …
Y Gao, H Li, L Qiu, H Yuan, Q Fan, Z Niu… - Science …, 2024 - journals.sagepub.com
Purpose: Programmed death-1 antibody plus chemotherapy has gained approval for the
treatment for (human epidermal growth factor receptor 2 negative locally advanced or …
treatment for (human epidermal growth factor receptor 2 negative locally advanced or …
Pembrolizumab in combination with chemotherapy in patients with advanced squamous cell lung cancer—clinical trials and real-world data
M Knetki-Wróblewska… - Oncology in Clinical …, 2024 - journals.viamedica.pl
Advanced squamous-cell lung carcinoma remains a disease with an unfavorable prognosi
s. Until recently, chemotherapy was used in systemic treatment, and its effectiveness was …
s. Until recently, chemotherapy was used in systemic treatment, and its effectiveness was …
Pembrolizumab w skojarzeniu z chemioterapią u chorych na zaawansowanego raka płaskonabłonkowego płuca—badania kliniczne wobec danych z codziennej …
M Knetki-Wróblewska… - Onkologia w Praktyce …, 2024 - journals.viamedica.pl
Zaawansowany rak płaskonabłonkowy płuca pozostaje nowotworem o niepomyślnym
rokowaniu. Do niedawna w leczeniu systemowym stosowano jedynie chemioterapię, której …
rokowaniu. Do niedawna w leczeniu systemowym stosowano jedynie chemioterapię, której …